Key result
Top-quartile hs-CRP predicts ~237% higher risk of adverse cardiac outcomes in high-risk Asian patients.
Cohort (n=347)
No
Relative Risk: 3.374 (95% CI 1.74–6.541)
p-value: p=<0.001
Elevated hs-CRP is a strong independent predictor of medium-term adverse cardiac events in high-risk Asian patients presenting with chest pain but no evidence of myocardial infarction.
May aid risk stratification in high-risk Asian chest pain patients; hypothesis-generating and requires prospective validation before guiding therapy.
INTRODUCTION: High-sensitivity C-reactive protein (hs-CRP) has been shown to be predictive of cardiac events but data among Asians is comparatively few. We evaluated the role of hs-CRP in the prediction of adverse cardiac outcome in a cohort of high-risk patients presenting with chest pain syndrome without myocardial infarction (MI). MATERIALS AND METHODS: Three hundred and forty-seven patients were prospectively recruited over an 18-month period and patients with MI as documented by serial electrocardiogram abnormalities, and creatinine kinase or troponin elevation were excluded. Mean follow-up duration was 901 +/- 306 days. Kaplan-Meier and Cox proportional hazards modelling were used to evaluate outcome and determine association with predictor variables. RESULTS: The composite primary endpoint of cardiac mortality, non-fatal MI, cardiac failure or coronary revascularisation procedure (coronary artery bypass grafting or angioplasty) unrelated to the index admission was reached in 37 patients. History of previous MI (P = 0.002), presence of at least 1 coronary artery with > or =50% stenosis (P = 0.028) and elevated hs-CRP levels were associated with an adverse cardiac outcome (P = 0.001 for CRP in the upper quartile, and 0.002 for CRP > or = 1mg/L, respectively). None of the traditional cardiovascular risk factors (hypertension, diabetes mellitus, dyslipidaemia, significant family history, smoking, male gender and increased age) was predictive. Multivariate modelling showed elevated hs-CRP to confer the highest risk for an adverse cardiac outcome (P <0.001). CONCLUSION: Hs-CRP is useful in further stratifying high-risk multi-ethnic patients presenting with chest pain despite no evidence of MI. Close follow-up and aggressive management of these patients may be warranted.
No takes yet. Share an insight, caveat, or question.
Low et al. (2004) conducted a cohort in Chest pain syndrome without myocardial infarction (n=347). Elevated high-sensitivity C-reactive protein (hs-CRP) vs. Lower hs-CRP levels was evaluated on Composite of cardiac mortality, non-fatal MI, cardiac failure or coronary revascularisation procedure unrelated to the index admission (RR 3.374, 95% CI 1.740-6.541, p=<0.001). Elevated high-sensitivity C-reactive protein levels in the upper quartile independently predicted a higher risk of adverse cardiac outcomes (RR 3.374) in high-risk Asian patients with chest pain.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: